USPSTF Cervical Cancer Screening Recommendations
The USPSTF recommends screening women aged 21-65 years with cytology (Pap smear) every 3 years, or for women aged 30-65 years, screening with cytology plus HPV testing (co-testing) every 5 years, or primary HPV testing alone every 5 years 1, 2.
Age-Specific Screening Algorithm
Women Ages 21-29 Years
- Screen with cytology alone every 3 years (Grade A recommendation) 1, 2
- Do NOT use HPV testing (alone or with cytology) in this age group—it provides no additional benefit and increases harms from detecting transient HPV infections that will clear spontaneously 1
Women Ages 30-65 Years
You have three equally acceptable options 2:
- Cytology alone every 3 years
- Primary HPV testing alone every 5 years (preferred in 2018 update)
- Co-testing (cytology + HPV) every 5 years
The 5-year intervals with HPV-based strategies provide similar mortality reduction to 3-year cytology while reducing screening frequency and associated harms 1.
Do NOT Screen These Groups
Women under age 21 (Grade D recommendation) 1:
- Screening provides no mortality benefit regardless of sexual history
- Causes substantial harm from overdetection of lesions that would regress spontaneously
Women over age 65 with adequate prior screening (Grade D recommendation) 1:
- "Adequate screening" means negative results on 3 consecutive cytology tests OR 2 consecutive co-tests within the past 10 years, with the most recent test within 5 years
- Exception: Continue screening if history of CIN 2/3 or cervical cancer
Women post-hysterectomy with cervix removal (Grade D recommendation) 1:
- Only if hysterectomy was for benign reasons
- Exception: Continue screening if history of high-grade precancerous lesion (CIN 2/3) or cervical cancer
Critical Caveats
These recommendations do NOT apply to 1:
- Women with history of high-grade precancerous lesions or cervical cancer
- Immunocompromised women (including HIV-positive)
- Women with in utero diethylstilbestrol exposure
These high-risk groups require more intensive surveillance protocols beyond standard screening guidelines.
Evidence Strength
The USPSTF gives these recommendations an A grade, indicating high certainty that the net benefit is substantial 1, 2. The evidence shows cervical cancer deaths decreased dramatically from 2.8 to 2.3 per 100,000 women between 2000-2015 with widespread screening implementation 2. Most cervical cancers occur in women who were never appropriately screened 1.
Note: A 2018 USPSTF update added primary HPV testing every 5 years as a preferred option for ages 30-65, reflecting new evidence on HPV test performance 2, 3. The core age ranges and cytology recommendations from 2012 remain unchanged.